Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03880539
Other study ID # Study00143405
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date June 25, 2019
Est. completion date November 18, 2021

Study information

Verified date May 2022
Source University of Kansas Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a research study to collect information from people that have Clostridium difficile infection (CDI) and are treated with a standard antibiotic treatment in which the antibiotic dose is gradually reduced over 6 weeks and bezlotoxumab (BEZLO), an approved monoclonal antibody targeting C. difficile toxin, which has shown to reduce CID recurrence when used in combination with standard antibiotic treatment.


Description:

Clostridium difficile (C. diff) is a type of bacteria which causes diarrhea in some people who receive antibiotics for other infections. The current antibiotics used to treat C diff infection (CDI) are usually successful in treating the initial episode of CDI, but may not prevent recurrent infection. To prevent recurrent CDI, standard oral antibiotic treatment with vancomycin is extended by gradually reducing the dose over 4-8 weeks. This is called antibiotic taper. Bezlotoxumab (BEZLO), a monoclonal antibody targeting C. difficile toxin B, is an approved medication that has also been shown to reduce CDI recurrence in patients receiving antibacterial drug treatment of CDI. In this study, approximately 12 people with multi-recurrent CDI will be treated with BEZLO in combination with standard oral tapered vancomycin. Study participation will last 16 weeks. The rate of CDI recurrence in this group will be compared to information collected from approximately 72 historical patients with multi-recurrent CDI treated with oral tapered vancomycin only.


Recruitment information / eligibility

Status Completed
Enrollment 4
Est. completion date November 18, 2021
Est. primary completion date November 18, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria (Interventional): - i) age 18 years or older; - ii) diagnosis of multi-recurrent CDI, defined as passage of 3 or more loose stools in 24 hours or less for at least 2 consecutive days and a positive stool test for toxigenic C. difficile (nucleic acid amplification test [NAAT] and toxin enzyme immunoassay [EIA] positive), with 2 or more confirmed prior CDI episodes; - iii) receiving or planning to receive a 10- to 14-day course of SOC therapy with oral VAN followed by a tapered VAN regimen for at least 4 weeks; - iv) patient highly unlikely to become pregnant due to being female and not of reproductive potential or female of reproductive potential agreeing to be abstinent or using 2 acceptable methods of birth control starting at enrollment and through the 16-week study period; and - v) patient or legal representative voluntarily agreeing to participate by providing written informed consent after the nature of the study has been fully explained. Inclusion Criteria (Historical Control): - i) age 18 years or older - ii) diagnosis of multi-recurrent CDI - iii) received 10- to 14-day course of SOC therapy with oral VAN followed by a tapered VAN regimen. Exclusion Criteria: - i) active chronic diarrheal illness, such as (but not limited to) ulcerative colitis or Crohn's disease or with a condition such that they routinely pass loose stool - ii) planned surgery for CDI within 24 hours - iii) positive pregnancy test in the 48 hours before the infusion or unwilling to undergo pregnancy testing if a pre-menopausal female who is not sterilized and therefore has the potential to bear a child - iv) breastfeeding or planning to breastfeed prior to the completion of the study period - v) previous receipt of BEZLO - vi) receipt of immune globulin within 6 months prior to enrollment or planning to receive immune globulin prior to completion of the 16-week study period - vii) receipt of non-SOC CDI therapy within 14 days prior to enrollment - viii) planned treatment with SOC therapy for longer than 6 weeks - ix) receipt of medications to control diarrhea such as loperamide, diphenoxylate hydrochloride/atropine sulfate at any time prior to completion of the 16-week study period - x) medical history of decompensated congestive heart failure

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
bezlotoxumab
Adding BEZLO to SOC oral VAN pulse/taper
Vancomycin Oral
SOC vancomycin pulse/taper

Locations

Country Name City State
United States University of Kansas Medical Center Kansas City Kansas

Sponsors (2)

Lead Sponsor Collaborator
University of Kansas Medical Center Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of CDI reoccurrence at 12 weeks If diarrhea resolves (defined as <2 loose stools per day for at least 2 consecutive days) and subsequently begins again (3 or more loose stools in 24 hours or less for at least 2 consecutive days), this will represent a new episode of diarrhea. If there is a new episode of diarrhea at any time during the 12-week study period, an unscheduled visit will be conducted. A stool sample will be provided for any new episode of diarrhea which occurs and a stool test for toxigenic C. difficile (NAAT plus EIA) will be performed. CDI reoccurrence will be defined as new episode of diarrhea and positive stool test for toxigenic C. difficile (NAAT plus EIA). 12 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04000555 - Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI) Phase 4
Terminated NCT03065374 - Treatment for Clostridium-difficile Infection With IMM529 Phase 1/Phase 2
Not yet recruiting NCT05606159 - Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections N/A
Completed NCT03110133 - Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff Phase 2
Recruiting NCT06237452 - VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 3
Not yet recruiting NCT04415918 - Bezlotoxumab Efficacy and Tolerability in Cancer Patient Phase 4
Recruiting NCT03562741 - Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile N/A
Completed NCT03788434 - Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 2
Completed NCT04891965 - A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI) Phase 1
Completed NCT04317963 - Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection
Completed NCT03617445 - Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients Phase 2
Recruiting NCT05831189 - A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection Phase 3